| Wang, Fei |
NCT06269445: The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer |
|
|
| Recruiting | 4 | 20 | RoW | Icaritin Combined With Bevacizumab and FOLFIRI | Sir Run Run Shaw Hospital | Colorectal Cancer | 02/25 | 02/26 | | |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05369078: Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects |
|
|
| Recruiting | 1 | 16 | RoW | THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group | Newsoara Biopharma Co., Ltd. | T2DM (Type 2 Diabetes Mellitus) | 05/22 | 05/22 | | |
NCT06561997: Enhancing Thoracolumbar Burst Fracture Treatment |
|
|
| Completed | N/A | 182 | RoW | Robot-assisted, Free-hand | Peng Liu | Surgery | 06/19 | 06/20 | | |
FLAT, NCT03805191: A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 900 | RoW | | Qilu Hospital of Shandong University, Bayer | Type 2 Diabetes Mellitus, Poor Glycemic Control | 11/20 | 12/22 | | |
NCT04658992: The Registration on the Use of Feilike Heji in Minors |
|
|
| Recruiting | N/A | 3000 | RoW | | China Academy of Chinese Medical Sciences | Bronchial Asthma | 12/21 | 03/22 | | |
NCT05949736: Effect of Music Therapy in Medical Students (EMTMS) |
|
|
| Recruiting | N/A | 200 | RoW | The Online intervention platform | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety, Insomnia | 08/23 | 05/25 | | |
| Recruiting | N/A | 60 | RoW | Group Cognitive Behavioral Therapy (GCBT) | Jiangsu Province Nanjing Brain Hospital | Mental Suffering | 09/23 | 01/24 | | |
NCT05648539: Effect of Music Therapy in Mental Subhealth (EMTMS) |
|
|
| Recruiting | N/A | 150 | RoW | The mini apps named "SOUL GYM" on the Wechat | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety | 10/23 | 10/27 | | |
| Recruiting | N/A | 120 | RoW | Active rTMS, VISHEE Magneuro stimulator, Sham rTMS | Jiangsu Province Nanjing Brain Hospital | Major Depressive Episode | 07/24 | 07/24 | | |
NCT06238869: Online Mental Health Interventions for Children and Adolescents (OMHICA) |
|
|
| Enrolling by invitation | N/A | 7000 | RoW | Computerized Cognitive Behavioral Therapy, Music Therapy, Health education | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety, Stress, Insomnia | 09/25 | 12/25 | | |
NCT05681364: Prediction of Pulmonary Rehabilitation Outcomes in Patients With Chronic Respiratory Disease Based on Metabolomics: a Prospective Cohort Study |
|
|
| Not yet recruiting | N/A | 300 | NA | metabonomics | Peking University Third Hospital | Chronic Obstructive Pulmonary Disease, Bronchiectasis | 12/24 | 12/24 | | |
PRHDTDCSTMDE, NCT05498441: Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Treatment for Major Depressive Episode |
|
|
| Recruiting | N/A | 120 | RoW | High-Definition Transcranial Direct Current Stimulation (HD-tDCS), Antipsychotics, mood stabilizers, etc. | Jiangsu Province Nanjing Brain Hospital | Major Depressive Episode | 12/24 | 12/24 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
| Gao, Yongsheng |
NCT06385379: Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study) |
|
|
| Recruiting | N/A | 90 | RoW | WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system | Hangzhou Endonom Medtech Co., Ltd. | Aortic Arch Aneurysm | 12/25 | 12/30 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
| Li, Shanshan |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
VGR-R01-301, NCT06699108: Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy |
|
|
| Not yet recruiting | 3 | 45 | RoW | VGR-R01 | Shanghai Vitalgen BioPharma Co., Ltd. | Bietti Crystalline Dystrophy, Inherited Retinal Diseases | 12/26 | 06/27 | | |
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 2 | 41 | RoW | BDB-001 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 08/23 | 08/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 1/2 | 50 | RoW | BDB-001 Injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 07/23 | 07/23 | | |
| Recruiting | N/A | 140 | RoW | sham stimulation, intermittent theta-burst stimulation (iTBS) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Mental Health Center, The Affiliated Kangning Hospital of Ningbo University, The First Affiliated Hospital of Anhui Medical University | Posttraumatic Stress Disorder | 12/25 | 05/26 | | |
| Yang, Liming |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
